Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Nov 25;8(11):e81539.
doi: 10.1371/journal.pone.0081539. eCollection 2013.

Population genetic structure of Streptococcus pneumoniae in Kilifi, Kenya, prior to the introduction of pneumococcal conjugate vaccine

Affiliations

Population genetic structure of Streptococcus pneumoniae in Kilifi, Kenya, prior to the introduction of pneumococcal conjugate vaccine

Angela B Brueggemann et al. PLoS One. .

Abstract

Background: The 10-valent pneumococcal conjugate vaccine (PCV10) was introduced in Kenya in 2011. Introduction of any PCV will perturb the existing pneumococcal population structure, thus the aim was to genotype pneumococci collected in Kilifi before PCV10.

Methods and findings: Using multilocus sequence typing (MLST), we genotyped >1100 invasive and carriage pneumococci from children, the largest collection genotyped from a single resource-poor country and reported to date. Serotype 1 was the most common serotype causing invasive disease and was rarely detected in carriage; all serotype 1 isolates were members of clonal complex (CC) 217. There were temporal fluctuations in the major circulating sequence types (STs); and although 1-3 major serotype 1, 14 or 23F STs co-circulated annually, the two major serotype 5 STs mainly circulated independently. Major STs/CCs also included isolates of serotypes 3, 12F, 18C and 19A and each shared ≤ 2 MLST alleles with STs that circulate widely elsewhere. Major CCs associated with non-PCV10 serotypes were predominantly represented by carriage isolates, although serotype 19A and 12F CCs were largely invasive and a serotype 10A CC was equally represented by invasive and carriage isolates.

Conclusions: Understanding the pre-PCV10 population genetic structure in Kilifi will allow for the detection of changes in prevalence of the circulating genotypes and evidence for capsular switching post-vaccine implementation.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: ABB and JAGS each have vaccine-related research funding from GlaxoSmithKline Biologicals; JAGS has received conference support from Merck, Inc. Other authors declare no conflicts of interest. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.

Figures

Figure 1
Figure 1. Prevalence of major clonal complexes (CCs) associated with invasive isolates collected in Kilifi.
The total number of isolates genotyped each year from 1994-2008 is stated in parentheses in the y-axis labels.
Figure 2
Figure 2. Fluctuation in the prevalence of major sequence types (STs) associated with invasive isolates from Kilifi.
Invasive isolates were collected from 1994-2008 and the major STs associated with serotypes 1 (Figure 2A) and 5 (Figure 2B) are depicted in each panel. The total number of isolates genotyped each year (see Methods) is stated in parentheses in the x-axis labels.
Figure 3
Figure 3. Fluctuation in the prevalence of major sequence types (STs) associated with invasive isolates from Kilifi.
Invasive isolates were collected from 1994-2008 and the major STs associated with serotypes 14 (Figure 3A) and 23F (Figure 3B) are depicted in each panel. The total number of isolates genotyped each year (see Methods) is stated in parentheses in the x-axis labels.
Figure 4
Figure 4. Five additional major sequence types (STs) associated with invasive isolates that circulated in Kilifi.
Major STs associated with serotypes 12F, 19A, 6B, 4 and 18C are depicted for each surveillance year from 1994-2008. The total number of isolates genotyped each year (see Methods) is stated in parentheses in the x-axis labels.

Similar articles

Cited by

References

    1. Flasche S, Van Hoek AJ, Sheasby E, Waight P, Andrews N et al. (2011) Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: a cross-sectional study. PLoS Med 8: e1001017 PubMed: 21483718. - PMC - PubMed
    1. Centers for Disease Control and Prevention (CDC) (2005) Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United States, 1998-2003. MMWR Morb Mortal Wkly Rep 54: 893-897. PubMed: 16163262. - PubMed
    1. O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M et al. (2009) Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 374: 893-902. doi:10.1016/S0140-6736(09)61204-6. PubMed: 19748398. - DOI - PubMed
    1. Black RE, Cousens S, Johnson HL, Lawn JE, Rudan I et al. (2010) Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet 375: 1969-1987. doi:10.1016/S0140-6736(10)60549-1. PubMed: 20466419. - DOI - PubMed
    1. Centers for Disease Control and Prevention (CDC) (2013) Progress in introduction of pneumococcal conjugate vaccine - worldwide, 2000-2012. MMWR Morb Mortal Wkly Rep 62: 308-311. PubMed: 23615674. - PMC - PubMed

Publication types

Substances